Foamable vehicle and pharmaceutical compositions thereof
First Claim
Patent Images
1. A hygroscopic pharmaceutical composition in a pressurized container comprising:
- a. at least one hygroscopic substance at a sufficient concentration to provide an Aw value of the hygroscopic pharmaceutical composition of less than 0.9, wherein the hygroscopic substance comprises a polyethylene glycol (PEG) or a polyol;
b. an anti-infective agent;
c. about 0.01% to about 5% by weight of at least one polymeric agent, wherein the polymeric agent is a gelling agent;
d. about 0.2% to about 5% by weight of a surface-active agent; and
e. a liquefied or compressed gas propellant;
wherein the composition comprises not more than 10% or about 10% water by weight; and
wherein the composition forms a breakable foam upon dispensing from the pressurized container.
8 Assignments
0 Petitions
Accused Products
Abstract
A hygroscopic pharmaceutical composition includes at least one hygroscopic substance at a concentration sufficient to provide an Aw value of at least 0.9 and an antiinfective agent. A foamble pharmaceutical carrier includes about 50% to about 98% of a polar solvent selected from the group consisting of a polyol and PEG; 0% to about 48% of a secondary polar solvent; about 0.2% to about 5% by weight of a surface-active agent; about 0.01% to about 5% by weight of at least one polymeric agent; and a liquefied or compressed gas propellant at a concentration of about 3% to about 25% by weight of the total composition.
-
Citations
75 Claims
-
1. A hygroscopic pharmaceutical composition in a pressurized container comprising:
-
a. at least one hygroscopic substance at a sufficient concentration to provide an Aw value of the hygroscopic pharmaceutical composition of less than 0.9, wherein the hygroscopic substance comprises a polyethylene glycol (PEG) or a polyol; b. an anti-infective agent; c. about 0.01% to about 5% by weight of at least one polymeric agent, wherein the polymeric agent is a gelling agent; d. about 0.2% to about 5% by weight of a surface-active agent; and e. a liquefied or compressed gas propellant; wherein the composition comprises not more than 10% or about 10% water by weight; and wherein the composition forms a breakable foam upon dispensing from the pressurized container. - View Dependent Claims (2, 3, 4, 72, 75)
-
-
5. A foamable pharmaceutical carrier in a pressurized container comprising:
-
a. about 50% to about 98% of a polar solvent selected from the group consisting of (1) a polyol and (2) a polyethylene glycol (PEG); b. 0% to about 48% of a secondary polar solvent; c. about 0.2% to about 5% by weight of a surface-active agent; d. about 0.01% to about 5% by weight of at least one polymeric agent selected from a bioadhesive agent, a gelling agent, a film forming agent and a phase change agent; and e. a liquefied or compressed gas propellant at a concentration of about 3% to about 25% by weight of the total composition; wherein the carrier comprises not more than 10% or about 10% water by weight and wherein the carrier forms a breakable foam upon dispensing from the pressurized container. - View Dependent Claims (6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 73)
-
-
41. A foamable therapeutic composition in a pressurized container comprising:
-
a. a therapeutically effective concentration of an active agent; b. about 50% to about 98% of a polar solvent selected from the group consisting of(1) a polyol; and
(2) a polyethylene glycol;c. 0% to about 48% of a secondary polar solvent; d. about 0.2% to about 5% by weight of a surface-active agent; e. about 0.01% to about 5% by weight of at least one polymeric agent selected from a bioadhesive agent, a gelling agent, a film forming agent and a phase change agent; and f. a liquefied or compressed gas propellant at a concentration of about 3% to about 25% by weight of the total composition. wherein the composition comprises not more than 10% or about 10% water by weight and wherein, the composition forms a breakable foam upon dispensing from the pressurized container. - View Dependent Claims (42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 74)
-
-
56. A method of treating a disorder of mammalian subject, comprising:
-
administering a foamable therapeutic composition to a target site, the composition comprising; a. a therapeutically effective concentration of an active agent; b. about 50% to about 98% of a polar solvent selected from the group consisting of(1) a polyol; and
(2) a polyethylene glycol;c. 0% to about 48% of a secondary polar solvent; d. about 0.2% to about 5% by weight of a surface-active agent; e. about 0.01% to about 5% by weight of at least one polymeric agent selected from a bioadhesive agent, a gelling agent, a film forming agent and a phase change agent; and f. a liquefied or compressed gas propellant at a concentration of about 3% to about 25% by weight of the total composition; wherein the composition comprises not more than 10% or about 10% water by weight; and wherein the composition forms a breakable foam upon dispensing from a pressurized container. - View Dependent Claims (57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71)
-
Specification